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Abstract 
Background: Although various alterative models of therapy are used for cartilage 
repair, no definite conclusion has been reached. Glucosamine (GlcN) is widely used 
as a nutritional supplement. However, the clinical‑ evidence‑based outcome of GlcN 
administration remains controversial. N‑acetyl‑d‑glucosamine (GlcNAc), a derivative 
of GlcN, shows chondroprotective activity and mediates the activation of articular 
chondrocytes. Therefore, we investigated the effect of intra‑articular administration of 
GlcNAc in rabbits’ knee joints with experimental full‑thickness articular cartilage (FTAC) 
defects.
Methods: Twelve male adult New Zealand white rabbits, providing 24 knees, were 
used in this study. FTAC defects were created in the high‑weight‑bearing area of the 
medial femoral condyles of bilateral knees. All rabbits were randomly allocated to 
analysis at postsurgical week 4 or postsurgical week 12. In the week 4 group, rabbits’ 
knees (six per group) were intra‑articularly injected with normal saline or with GlcNAc 
twice per week for 3 weeks, beginning 1 week postoperatively. In the week 12 group, 
the rabbits’ knees (six in each group) were intra‑articularly injected with normal saline 
or with GlcNAc twice per week for 4 weeks, beginning 1 week postoperatively. Rabbits 
were sacrificed at 4 or 12 weeks after surgery for macroscopic, histological and radio‑
logical examinations of the knee joints.
Results: All rabbits had no systemic or local adverse effects. The saline and GlcNAc 
groups showed visible differences in healing of the FTAC defect at the end of testing. 
At week 4, the GlcNAc group had a higher level of collagen type II (COL II) and showed 
up‑regulated production of transforming growth factor (TGF)‑β2 and TGF‑β3, suggest‑
ing the involvement of endogenous growth factors. At week 12, the GlcNAc group 
displayed formation of hyaline‑like cartilage regeneration with mature chondrocytes 
(SOX9+), robust glycosaminoglycan (GAG) content, and positive COL II content in both 
the adjacent cartilage and reparative sites. However, the saline group demonstrated 
mainly fibrocartilage scar tissue, indicating COL I expression. Furthermore, the GlcNAc 
group had significantly higher bone volume per tissue volume and higher trabecular 
thickness than the saline group.
Conclusions: Intra‑articular GlcNAc may promote the repair of experimental FTAC 
defects in the rabbit knee joint model.
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Background
The repair of articular cartilage defects is particularly challenging because of cartilage’s 
hypocellularity and insufficient nutrient supply, and the inability of bone marrow stem 
cells or resident chondroprogenitor cells to form hyaline cartilage. Current clinical ther-
apeutic treatments for cartilage repair include intra-articular therapy, e.g., non-steroidal 
anti-inflammatory drugs, corticosteroids, dextrose prolotherapy, hyaluronic acid (HA) 
or platelet-rich plasma [1, 2], microfracture, autologous chondrocyte implantation, and 
osteochondral transplantation techniques [3, 4]. However, these treatment options, par-
ticularly for large cartilage defects, present not only the formation of fibrocartilage scar 
tissue but also poor integration of hyaline cartilage in the host [5, 6]. Hence, regarding 
their effectiveness for large cartilage lesions, there is a lack of both clinical consensus 
and reproducible evidence that currently available treatment significantly changes the 
progression of osteoarthritis, based on prospective, randomized studies [7–9]. Thus far, 
no defined conclusion for cartilage repair has been reported.
Glucosamine (GlcN) is one of the most widely utilized dietary supplements. It is also 
believed to stimulate the metabolism of chondrocytes, thus providing beneficial effects 
on articular health. However, the clinical outcomes of GlcN administration orally remain 
controversial due to the various formulations and purity of GlcN [10–13]. GlcN intake 
as a nutritional supplement is commercially available in one of three forms: GlcN hydro-
chloride, GlcN sulfate, and N-acetyl-d-glucosamine (GlcNAc). Since a molecule of pure 
GlcN is essentially unstable, it should be salt-stabilized (e.g., chloride or sulfate) [14]. In 
particular, GlcNAc, classified as a monosaccharide derived from glucose, has a relatively 
stable structure.
Articular cartilage repair is determined by the growth microenvironment in the syn-
ovial joint. Ex vivo, administration of GlcN may modify disease activity, but a higher 
concentration of GlcN (>10 mM) depresses glucose transport, leading to decreased cell 
viability, depletion of proteoglycan synthesis, and further damage to the articular car-
tilage [15]. However, high concentrations of GlcNAc (>50  mM) have no inhibition on 
proteoglycan synthesis [16]. Previous in vitro studies reported that GlcNAc potentially 
promotes chondrogenesis of mesenchymal stem cells and enhances HA and glycosami-
noglycan (GAG) synthesis [17]. Furthermore, GlcNAc can be hydrolyzed to GlcN both 
in  vivo and in  vitro in applications for cartilage regeneration and anti-inflammatory 
activity [18–23]. Regarding pharmacokinetics, clinically relevant dosing of glucosamine 
HCl in serum and synovial fluid concentrations that are at least 500 fold lower than 
those reported to modify chondrocyte anabolic and catabolic activities in tissue and cell 
culture experiments. Most of the dietary glucosamine on pain and joint space may be 
secondary to its effects on nonarticular tissues, such as the intestinal lining, liver, or kid-
ney, since these may be exposed to much high levels of glucosamine following ingestion 
[24]. In other words, GlcN is almost absorbed from the gastrointestinal tract through 
oral administration, but very little diffuse into articular cartilage [25]. On the other hand, 
intravenous injection of GlcN within 1  h, approximately 30 percent is excreted in the 
urine. Some may be excreted in the gut, and the remainder is metabolized in the body 
[26]. Alternatively, local intra-articular injection with the preferred agent can directly 
supply an in  situ requirement of the growth microenvironment. Moreover, compared 
to GlcN, GlcNAc has been shown to have different biological activities including uptake 
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and effects on glucose transport, glucose transporter expression, and synthesis of sul-
fated GAG and HA [27]. A previous study investigated oral GlcNAc and GlcN admin-
istration on plasma total free amino acid (PFAA) concentrations in dogs [28]. GlcNAc 
group has the higher Glu, Gly, and Ala concentrations after 1 h administration compared 
with GlcN group. The three kind of non essential amino acid are the main components 
of type II collagen in cartilage.
Therefore, we investigated whether intra-articular injection of GlcNAc could provide 




GlcNAc (molecular formula: C8H15NO6) was purchased from Sigma (SI-A3286, MO, 
USA). It was dissolved in 0.9 % saline solution, and sterile filtered The sterilized solution 
was stored at 4 °C.
Surgical procedure
All surgical procedures and animal ethics were approved by the Animal Care and Use 
Committee of National Cheng Kung University. Twelve 4–5-month-old male New Zea-
land white rabbits (Livestock Research Institute, Taiwan) weighing 2.5–3 kg were used in 
this experiment, providing 24 knees. Before surgery, anesthesia was induced with Zoletil 
50 (25 mg/kg) (Virbac, France) and maintained with a mixture of 2 % isoflurane (Pan-
ion & BF Biotech Inc., Taiwan) and oxygen/nitrous oxide (1/0.4 L/min). Both knees of 
each rabbit were shaved and disinfected with 10 % ethanol-iodine solution. Longitudinal 
incisions were made along the parapatellar and capsular ligaments. The medial femo-
ral condyle was exposed by lateral patellar dislocation. A critical FTAC defect, 3 mm in 
diameter and 3 mm deep, was created with an electric drill in the high-weight-bearing 
region of the medial femoral condyle, simultaneously irrigated with saline for cooling, 
followed by patellar relocation and joint closure. After surgery, the rabbits were permit-
ted to move freely in their cages. Appetite, body weight, skin wound healing and func-
tional activities were monitored.
Intra‑articular injection
Each animal was given either saline or GlcNAc. At 7 days after surgery, in the week 4 
group, rabbits’ knees (six knees per group) were injected with 0.3  ml of normal ster-
ile saline (0.9 % NaCl) or intra-articularly with GlcNAc solution twice per week start-
ing 1 week post-surgery for a period of 3 weeks. In the week 12 group, rabbits’ knees 
(six knees per group) were injected with normal saline or intra-articularly with GlcNAc 
twice per week starting 1 week post-surgery for a period of 4 weeks. The single dose of 
GlcNAc was 80 mg/0.3 ml per joint. In addition, the recommended frequency of intra-
articular injection for optimal therapeutic efficacy is twice per week [18].
Macroscopic evaluation
At the end of testing, the outcome of the FTAC defect was first observed via macro-
scopic appearance based on the modified Wayne’s grading scores (Table  1) [29]. The 
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neo-tissue coverage, color and surface condition were assessed independently by two 
investigators. The maximum possible total score was 12 points.
Micro‑CT evaluation
Micro-computed tomography (CT) can provide quantitative and qualitative measure-
ments to identify the healing of bone architecture. A high-resolution microtomograph 
1076 scanner (SkyScan, Kontich, Belgium) was employed to scan the distal femur FTAC 
defect in the saline and GlcNAc groups at 4 and 12 weeks after surgery. The voltage and 
beam current of the X-ray source were set at 50 kV and 160 μA, respectively. The pixel 
size was set at 18 μm in resolution. The samples were scanned with 360° rotation with 1° 
of rotation interval.
The SkyScan software package, including SkyScan CT-Analyzer v.1.8, and CT-Volume 
v.2.0, were used to reconstruct the image data and visualize the representation of the 
newly formed bone. From the data set, a cylindrical region of interest (ROI) 3 mm in 
diameter within the repaired site was selected for analysis. This ROI corresponds to 
the original defect region. The bone volume per tissue volume (BV/TV) and trabecular 
thickness (Tb.Th) were obtained to evaluate the bone volume density and to measure the 
thickness of trabecular structures, respectively.
Histological and immunohistochemistry processing
All histological sections were performed by the Department of Pathology at Chi-Mei 
Medical Center. The femur ends were dissected, fixed in 10 % neutral buffered formal-
dehyde solution, decalcified and embedded in paraffin blocks. From each sample, the 
tissue was sliced by a microtome into 4  μm thick sections for histological staining. 
Hematoxylin and eosin (H&E) staining was performed to allow general observations; 
Table 1 A modified Wayne’s grading scale scoring system for gross appearance
Macroscopic appearance Points
Coverage
 >75 % fill 4
 50–75 % fill 3
 25–50 % fill 2
 <25 % fill 1
 0 % fill 0
Tissue color
 Normal/whitish 4
 >25 % yellow/reddish 3
 >50 % yellow/reddish 2
 >75 % yellow/reddish 1
 100 % yellow/reddish 0
Surface
 Normal, smooth 4
 Smooth but raised 3
 25–50 % irregularity/fibrillation 2
 50–75 % irregularity/fibrillation 1
 >75 % irregularity/fibrillation 0
Total 12
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Masson’s trichrome stain was used for total collagen and alignment; Alcian blue staining 
was performed for GAG synthesis. Furthermore, immunohistochemistry analysis was 
conducted to confirm the expression of collagen type I (COL I, fibrocartilage), collagen 
type II (COL II, hyaline cartilage), endogenous growth factors (i.e., TGFβ-2 and TGFβ-
3) as well as SOX9 (marker of mature chondrocytes) for the repair of FTAC defects. All 
staining protocols followed the manufacturers’ recommended guidelines. Briefly, the 
sections were treated with endogenous peroxidase and incubated overnight with a mon-
oclonal primary antibody diluted 1:100: COL I (Bioworld Technology), COL II (Bioss), 
TGFβ-2 or TGFβ-3 (Spring Bioscience), or SOX9 (Bioss). The rabbit/mouse HRP-DAB 
polymer detection kit (BioSB) was used as the secondary antibody at room temperature 
for 30 min. Then, DAB (3,3′ diaminobenzidine) staining in brown represented positive 
immunoreactivity. The sections were counterstained with hematoxylin (BioSB) and then 
recorded using a light microscope (Olympus IX71, Tokyo, Japan) and a digital CCD 
camera (Olympus DP72, Tokyo, Japan).
Statistical analysis
The software package SPSS v17.0 was used for the statistical analysis. All of the data 
(six knees per group at week 4 or 12) are expressed as the mean ±  standard error of 
the mean. Owing to the concern of repeated measurements from bilateral knees on the 
same individual [30], a linear model using generalized estimating equations (GEE) was 
employed for statistical comparison at each time point. P-values <0.05 were defined as 
statistically significant. The statistical power of this study was 0.9 as determined by the 
mean, variation, and sample size.
Results
Macroscopic observations and scoring in the FTAC model
The gross appearance of FTAC defects was assessed at both 4 and 12 weeks after surgery 
(Fig.  1a). No infection, synovitis or osteophyte formation was observed at either time 
point. At week 4, the defect areas in both the saline and GlcNAc groups were visibly 
concave although new tissue had developed inwards from the outer area of the defect 
edges. At week 12, the GlcNAc group had formed a transparent neo-cartilage-like tissue. 
Meanwhile, the saline group showed incomplete filling, with hybrid whitish/yellow tis-
sues and an obvious fissure in the reparative site (Fig. 1a).
The total scores in both saline (6.00 ± 0.40) and GlcNAc groups (7.33 ± 0.76) were 
comparable at week 4 after surgery. However, at week 12 after surgery, the total score for 
the GlcNAc group (8.33 ± 0.47) was superior to that for the saline group (5.36 ± 0.37). 
In addition, the GlcNAc group showed a significant increase in total scores from 4 to 
12 weeks (p < 0.01) (Fig. 1b).
Subchondral bone formation using Micro‑CT evaluation
Micro-CT images of medial condyles at weeks 4 and 12 after surgery are shown in 
Fig. 2a. The repairing pattern of newly mineralized tissue was edge-to-center, indicating 
development from the outer area of the defect. At week 4, regenerative osseous tissues 
in saline and GlcNAc groups were comparable. However, at week 12, the GlcNAc group 
had more newly osseous tissues and integrating trabecular bones than the saline group. 
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In addition, BV/TV and Tb.Th were used as measures of subchondral bone regenera-
tion. With respect to BV/TV, the values in the GlcNAc group (38.3 ± 3.5) were markedly 
higher than the saline group (30.0 ± 5.0), particularly at week 12 (Fig. 2b). The GlcNAc 
group had a 1.5-fold greater increase in BV/TV compared to the saline group from week 
4 to week 12 (Fig. 2b). Moreover, the GlcNAc group showed a significant increase in BV/
TV from week 4 (26.0 ± 2.6) to week 12 (38.3 ± 3.5) (p = 0.002) (Fig. 2b). With respect 
to Tb.Th, at 12 weeks, the values in the GlcNAc group (0.23 ± 0.01) were significantly 
higher than those in the saline group (0.19 ± 0.01) (p < 0.001). In addition, the GlcNAc 
group showed a significant increase in Tb.Th over time (p < 0.001) (Fig. 2b).
Fig. 1 a Representative images of the gross appearances at 4 and 12 weeks after operation. Circles indicate 
the repaired osteochondral defect area. b Quantitative scores of the gross appearance. #p < 0.01
Fig. 2 Analysis of bone regeneration. a Micro‑CT images of bone assessment at 4 weeks and 12 weeks after 
operation. Circles indicate the repaired osteochondral defect area. b Quantitative scores of the ratio of bone 
volume to tissue volume (BV/TV) and of the thickness of trabecular bone (Tb.Th). #p < 0.001
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Histological findings
At 4 weeks after operation
In the saline group, the defect regions were filled with hyperplasic blood vessels, con-
tained disoriented fibrous tissue together with fibroblast-like cells, and showed a 
shortage of GAG synthesis (Fig.  3a). Furthermore, representative inflammatory cells, 
including plasma cells, lymphocytes and polymorphonuclear neutrophils (PMNs) were 
found in the reparative region (Fig. 3b).
However, in the GlcNAc group, the migration of undifferentiated chondroblasts 
together with increasing GAG synthesis had begun in the reparative regions at week 4. 
Furthermore, the GlcNAc group showed newly generated collagen matrix, coupled with 
underlying osteoid at the defect edges (Fig. 3a). Moreover, the GlcNAc group displayed 
higher levels of COL I and COL II than the saline group (Fig. 4). Surprisingly, the two 
Fig. 3 a Representative histological images of the repaired area using H&E, Masson’s trichrome, and Alcian 
blue staining at 4 and 12 weeks after operation. b The saline group contained representative inflammatory 
cells, including plasma cells (Pc), lymphocyte (Lc), polymorphonuclear neutrophils (PMN), basophil (Bp), 
eosinophil (Ep) and Macrophage (M), in the reparative regions at 4 weeks
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decisive endogenous growth factors (i.e., TGF-β2 and TGF-β3) were highly expressed 
compared to the saline group (Fig. 4).
At 12 weeks after operation
Compared to the saline group, the GlcNAc group showed obvious histological changes 
in both hyaline cartilage regeneration and subchondral bone formation (Fig.  3a). The 
saline group still showed irregular surfaces, disorganized collagen, and GAG depletion 
in the adjacent cartilage (Fig. 3a). In contrast, the GlcNAc group showed potential posi-
tive outcomes including the regeneration of hyaline-like cartilage corresponding with 
chondrocytes in lacunae (SOX9+), rich GAG content, reconstructed COL II content 
(hyaline cartilage) as well as low levels of COL I (fibrocartilage) in the adjacent cartilage 
and reparative site (Figs. 3a, 5). Furthermore, in the GlcNAc group, the trabecular bone 
was embedded with osteocytes, along with osteoid matrix surrounding osteoblasts, indi-
cating sound bone remodeling (Fig. 5).
Fig. 4 Immunohistochemistry of the reparative areas for the specific proteins COL I and COL II, TGF‑β2 and 
TGF‑β3, and SOX9
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Discussion
The fate of healing articular cartilage is fundamentally dependent on better healing in 
the early stages and mechanically subchondral bone regeneration [31]. In this study, the 
GlcNAc group showed higher levels of tissue calcification, indicating beneficial trends 
for higher BV/TV and Tb.Th.
The TGF-β superfamily plays significant roles in enhancing chondrocyte growth, 
chondrocyte proliferation and osteochondrogenic differentiation [25]. TGF-β2 can stim-
ulate chondrocyte proliferation and cartilage regeneration [32, 33]; TGF-β3 may act as 
a chemotactic molecule (i.e., biological cue) that can recruit bone marrow stem cells, 
induce the recruited stem cells toward chondrogenesis, and enhance the compressive 
properties of neocartilage [34]. Based on the current data, we thus suggest that direct 
manipulation of in situ microenvironments (i.e., GlcNAc injection) provides a better mix 
of endogenous growth factors and cytokines, especially in the early stage, for cartilage 
repair. In this study, GlcNAc showed no locally or systemically adverse reactions, con-
sistent with reported outcomes. Previous studies suggest that GlcNAc has an excellent 
safety profile in humans. In addition, it has been reported that GlcNAc has additional 
potential advantages over GlcN as a potential therapeutic anti-inflammatory agent. 
GlcN initiates phosphorylation by glucokinase and competes with glucose for binding to 
glucokinase in the cell [35], thereby giving rise to GlcN-induced insulin resistance [36]. 
In contrast, GlcNAc has much lower affinity toward glucokinase than do either glucose 
or GlcN; thus, it does not respond significantly to glucose metabolism [37].
Based on this study, one possible major reparative mechanism may function through 
changes to the in situ microenvironments in the reparative site. Transport of nutrients 
and a subset of signal molecules can be supplied from the synovial membrane to syno-
vial fluid [24]; as an alternative source, nutritional support also diffuses from subchon-
dral bone [38].
Fig. 5 At 12 weeks after operation, trabecular bone (Tb) embedded with mature osteocytes (Oc) in the 
reparative site was found in the GlcNAc group. Meanwhile, in the healing osteochondral defects, new osteoid 
matrix (Od) surrounding osteoblasts (Ob), was accompanied by remodeling
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Conclusions
This study demonstrated that intra-articular injection of GlcNAc is safe and has the poten-
tial to improve the repair of FTAC in the rabbit knee joint model. Promising outcomes 
include the improvement of damaged articular surface, formation of hyaline-like cartilage, 
rich GAG synthesis, and subchondral bone regeneration. This strategy warrants further 
investigation to support an effective transition from animal models to human patients.
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